PeriVision is the latest company to be awarded a place on Biopôle’s six-month acceleration programme, the Vanguard Accelerator, which is dedicated to supercharging early-stage companies and projects.
PeriVision, which has been selected by the Vanguard experts for the full support package, combines AI algorithms, virtual reality and cloud computing to build the next-generation systems to test visual function. The first target market is visual field testing in glaucoma patient monitoring. PeriVision’s solution addresses the large unmet need for higher workflow efficiency in practices and hospitals and deeper clinical insight to better manage the eye disease.
PeriVision’s support from Vanguard will include expert coaching, regular meetings to help the company access the healthcare network and digital health stakeholders, as well as personalised follow-up from a Vanguard expert about specific business strategy topics. PeriVision moved into the Biopôle Digital Health Hub at the beginning of July 2022.